Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade F 38.06 1.79% 0.67
URGN closed up 1.79 percent on Friday, March 15, 2019, on 70 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical URGN trend table...

Date Alert Name Type % Chg
Mar 15 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 15 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 15 Up 3 Days in a Row Strength 0.00%
Mar 13 Outside Day Range Expansion 3.28%
Mar 13 Oversold Stochastic Weakness 3.28%
Mar 12 Narrow Range Bar Range Contraction 5.69%
Mar 12 NR7 Range Contraction 5.69%
Mar 12 NR7-2 Range Contraction 5.69%
Mar 12 Oversold Stochastic Weakness 5.69%

Older signals for URGN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 34.63
Average Volume 234,612
200-Day Moving Average 46.1475
50-Day Moving Average 42.895
20-Day Moving Average 38.8515
10-Day Moving Average 37.308
Average True Range 1.7102
ADX 38.69
+DI 15.2229
-DI 27.9515
Chandelier Exit (Long, 3 ATRs ) 37.1894
Chandelier Exit (Short, 3 ATRs ) 39.7606
Upper Bollinger Band 42.8743
Lower Bollinger Band 34.8287
Percent B (%b) 0.4
BandWidth 20.708596
MACD Line -1.4895
MACD Signal Line -1.5776
MACD Histogram 0.088
Fundamentals Value
Market Cap 495.13 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -22.79
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.85
Resistance 3 (R3) 39.74 39.04 39.55
Resistance 2 (R2) 39.04 38.59 39.09 39.45
Resistance 1 (R1) 38.55 38.30 38.80 38.66 39.35
Pivot Point 37.85 37.85 37.97 37.90 37.85
Support 1 (S1) 37.36 37.40 37.61 37.47 36.77
Support 2 (S2) 36.66 37.11 36.71 36.67
Support 3 (S3) 36.17 36.66 36.57
Support 4 (S4) 36.28